BETA vs NEPHROPLUS: Stock Comparison
NEPHROCARE HEALTH SERV L is the larger company by market capitalisation. BETA DRUGS shows a lower P/E, a higher ROE and a higher ROCE, while NEPHROCARE HEALTH SERV L shows lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BETA leads 9; NEPHROPLUS leads 1 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | BETA | NEPHROPLUS |
|---|---|---|
| Live Price | ₹1,805.9 | ₹601.75 |
| Day Change | -1.89% | -0.22% |
| Volume | 15,899 | 1.08 L |
| 52-Week High | ₹2,807.9 | ₹781.5 |
| 52-Week Low | ₹990.1 | ₹446 |
| Distance from 52W High | -35.69% | -23% |
Valuation
| Metric | BETA | NEPHROPLUS |
|---|---|---|
| Market Cap | ₹2,011 Cr | ₹6,062 Cr |
| P/E Ratio | 35.56x | 47.24x |
| P/B Ratio | 4.19x | 5.09x |
| EPS | ₹18 | ₹3.19 |
| Book Value | ₹220.09 | ₹111.27 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | BETA | NEPHROPLUS |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 9.51% | 0% |
| Qtr Profit Growth | 16.98% | 0% |
Profitability & Leverage
| Metric | BETA | NEPHROPLUS |
|---|---|---|
| ROE | 14.79% | -0.83% |
| ROCE | 18.03% | 5.17% |
| Net Margin | 10.78% | 7.69% |
| Operating Margin | 16.79% | 7.3% |
| Debt to Equity | 0.6x | 0.01x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | BETA | NEPHROPLUS |
|---|---|---|
| Promoter Holding | 58.91%▼ 0.19 pp | 18.79%▼ 2.28 pp |
| FII Holding | 1.37%▲ 0.35 pp | 11.73%▲ 2.95 pp |
| DII Holding | 6.45%▲ 0.22 pp | 8.11%▼ 0.94 pp |
| Public Holding | 33.27%▼ 0.38 pp | 21.85%▲ 3.53 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BETA DRUGS and NEPHROCARE HEALTH SERV L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.